Cover Image

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination

Saved in:

Bibliographic Details
Main Authors:	Karina Soboleva (Author), Nirmal Kumar Shankar (Author), Madhavi Yadavalli (Author), Cátia Ferreira (Author), Nadia Foskett (Author), Kert Putsepp (Author), Lisa Beth Ferstenberg (Author), Magnus Nord (Author), Hugo Gomes da Silva (Author), Prakash Bhuyan (Author)
Format:	Book
Published:	Elsevier, 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

AZ arm: Delayed cutaneous reaction to ChAdOx1 nCoV-19 (AZD1222) vaccine
by: Wei-Kai Hung, et al.
Published: (2022)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
by: Jonathan D. Ho, MBBS, DSc, DipDermpath, et al.
Published: (2022)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
by: Piyarat Limpawittayakul, et al.
Published: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023)

Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
by: Michael Makris, et al.
Published: (2022)

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
by: Nussara Pakvisal, et al.
Published: (2022)

The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based studyResearch in context
by: Huyen A. Tran, et al.
Published: (2023)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
by: Kriangkrai Tawinprai, et al.
Published: (2022)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
by: Manabendra Basu, et al.
Published: (2024)

Erythrodermic psoriasis following ChAdOx1 nCOV-19 vaccination: A case report
by: Pei-Tzu Lin, et al.
Published: (2022)

Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
by: Anupa Mary Job, et al.
Published: (2022)

Psoriasis flare following ChAdOx1-S/nCoV-19 vaccination in patients with psoriasis under biologic treatment
by: Jen-Ping Chao, et al.
Published: (2021)

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review
by: Homa Faghihi, et al.
Published: (2023)

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association
by: Laíssa Fiorotti Albertino, et al.
Published: (2022)

Evans' syndrome following vaccination with ChAdOx1 nCoV-19 in a patient with new-onset localized scleroderma
by: Thilo Gambichler, et al.
Published: (2022)

Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report
by: Joanna Bokel, et al.
Published: (2022)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
by: Thachanun Porntharukchareon, et al.
Published: (2023)

Incidence of early adverse events following covishield (ChAdOx1 nCoV-19) vaccination: A prospective study
by: Gajanan D Velhal, et al.
Published: (2022)

Lymphadenopathy subsequent to Covishield (ChAdOx1 nCoV-19) Corona virus vaccine: ultrasound findings and clinical implications
by: Soumya Swaroop Sahoo, et al.
Published: (2022)

ChAdOx1 nCoV-19 vaccine and its self-reported adverse events: a cross-sectional study from Western Nepal
by: Arun Gautam, et al.
Published: (2021)

Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccine in an older patient: Minireview and a case report
by: Paulo Queiroz Luciano, et al.
Published: (2022)

Improved Symptoms of Peripheral Facial Nerve Palsy in ChAdOx1 nCoV-19 Vaccine Recipients Following Complex Korean Medicine Treatment
by: Woo Seok Jang, et al.
Published: (2022)

Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany
by: Thomas Thiele, et al.
Published: (2022)

Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
by: Vishakh C. Keri, et al.
Published: (2022)

Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
by: Hassan M. Al-Emran, et al.
Published: (2022)

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
by: Peter Nordström, et al.
Published: (2021)

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
by: Yao Rodion Konu, et al.
Published: (2021)

Adverse events following COVISHIELD (ChAdOx1nCoV-19) vaccination among health care workers in Sri Lanka; a multi-centre cross sectional survey
by: S.R. Manilgama, et al.
Published: (2022)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
by: Natalie Teh, et al.
Published: (2021)

Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
by: Subhash Thuluva, et al.
Published: (2023)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024)

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
by: Prasad S. Kulkarni, et al.
Published: (2024)

Sarcoidosis and Polymethyl Methacrylate (PMMA) Granulomas following COVID-19 Vaccination (ChAdOx1): Successful Treatment with Tofacitinib
by: Mayra Ianhez, et al.
Published: (2024)

Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
by: Sue Ann Costa Clemens, et al.
Published: (2022)

Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational studyResearch in context
by: Mangaiarkarasi S. Asokan, et al.
Published: (2024)

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
by: Nungruthai Suntronwong, et al.
Published: (2023)

A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters.
by: Neeltje van Doremalen, et al.
Published: (2019)

Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India
by: Anuradha S. Tripathy, et al.
Published: (2024)

Association between COVID-19 Vaccination (ChAdOx1-S) and Thromboembolic, Thrombocytopenic, Hemorrhagic Events: A Systematic Review and Meta-analysis of Analytical Epidemiological Studies
by: Raman S. Vaman, et al.
Published: (2024)